EGFR (Epidermal Growth Factor Receptor)


Hatil A. C. , Çiçek E. , Oyken M. , Erson-Bensan A. E.

Atlas of Genetics and Cytogenetics in Oncology and Haematology, vol.24, no.9, pp.325-332, 2020 (Refereed Journals of Other Institutions) identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 9
  • Publication Date: 2020
  • Doi Number: 10.4267/2042/70782
  • Title of Journal : Atlas of Genetics and Cytogenetics in Oncology and Haematology
  • Page Numbers: pp.325-332
  • Keywords: anti-EGFR, panitumumab, childhood, colorectal cancer, OVARIAN METASTASES, YOUNG-ADULTS, CARCINOMA, ADOLESCENTS, CHILDREN, CHEMOTHERAPY, BEVACIZUMAB, CHILDHOOD, SURVIVAL, HEREDITARY

Abstract

© 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology.ERBB family member epidermal receptor tyrosine kinase (EGFR) is composed of 28 exons and 27 introns. EGFR codes for 11 transcripts and 8 of them are protein coding. EGFR is a transmembrane glycoprotein that can be activated by several different ligands such as epidermal growth factor (EGF), transforming growth factor-alpha (TGFA), heparin-binding EGF-like growth factor (HBEGF), betacellulin (BTC), amphiregulin (AREG), epiregulin (EREG), and epigen (EPGN) (Singh, 2016). Ligand binding induces the dimerization of EGFR and autophosphorylation followed by a cascade of downstream phosphorylation events (Capuani et al., 2015). EGFR activation plays a key role in cell survival, proliferation, migration and differentiation (Purba, 2017).